menu
    • menu
    [{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Sun Yat-sen University \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sun Yat-sen University \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Oncology","graph2":"Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SciClone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SciClone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Oncology","graph2":"Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SciClone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SciClone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leadiant Biosciences \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Leadiant Biosciences \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"Second Affiliated Hospital, Soochow University","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Oncology","graph2":"Phase II","graph3":"Second Affiliated Hospital, Soochow University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Soochow University \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Second Affiliated Hospital, Soochow University \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"William B. Ershler, MD","sponsor":"Davita Clinical Research | Clinical Research Consultants, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"William B. Ershler, MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"William B. Ershler, MD \/ Davita Clinical Research | Clinical Research Consultants, LLC","highestDevelopmentStatusID":"8","companyTruncated":"William B. Ershler, MD \/ Davita Clinical Research | Clinical Research Consultants, LLC"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Jia Fan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Oncology","graph2":"Phase IV","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciClone Pharmaceuticals \/ Jia Fan","highestDevelopmentStatusID":"11","companyTruncated":"SciClone Pharmaceuticals \/ Jia Fan"}]

    Find Clinical Drug Pipeline Developments & Deals for Thymosin Alpha 1

    Menu

    Thymosin Alpha 1

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Second Affiliated Hospital, Soochow University

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Second Affiliated Hospital, Soochow University

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : SciClone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

                            Details : Thymalfasin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 30, 2023

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : SciClone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            William B. Ershler, MD

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            William B. Ershler, MD

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Davita Clinical Research | Clinical Research Consultants, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

                            Details : Thymalfasin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 11, 2020

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Davita Clinical Research | Clinical Research Consultants, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SciClone Pharmaceuticals

                            China arrow
                            AllPack Indonesia
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Smal...

                            Details : Thymosin Alpha 1 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 19, 2016

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SciClone Pharmaceuticals

                            China arrow
                            AllPack Indonesia
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Sma...

                            Details : Thymosin Alpha 1 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 19, 2016

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sun Yat-sen University

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Sun Yat-sen University

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : SciClone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Efficacy and Safety of Ta1 for Sepsis

                            Details : Thymosin Alpha 1 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sepsis.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 15, 2016

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : SciClone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SciClone Pharmaceuticals

                            China arrow
                            AllPack Indonesia
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Jia Fan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative ...

                            Details : Thymalfasin is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 02, 2014

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Jia Fan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Leadiant Biosciences

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : SciClone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatiti...

                            Details : Thymosin Alpha 1 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 10, 2010

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : SciClone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth